The answer so far

The contraceptive pill is taken by mouth, so what happens in the digestive system can matter. A change in a blood test, however, is not the same as directly measuring pregnancies.

Tirzepatide can change how an oral contraceptive is absorbed. US and UK guidance recommend extra precautions around starting tirzepatide and dose increases; EU Mounjaro information assesses the same kind of evidence differently. Semaglutide has a different evidence and guidance profile. Vomiting or severe diarrhoea can affect an oral pill separately, whichever medicine is involved. Ask a pharmacist or prescriber promptly about your exact products and situation.1234

On this page
  1. Why could tirzepatide matter?
  2. What do US, UK and EU sources say?
  3. What about semaglutide?
  4. Vomiting and diarrhoea are a separate issue
  5. Planning pregnancy or breastfeeding
  6. Sources
Follow this question
Do tirzepatide or semaglutide affect the contraceptive pill? Choose a step to explore this subject in more detail.
  1. 1Why could tirzepatide matter?
  2. 2What do US, UK and EU sources say?
  3. 3What about semaglutide?
  4. 4Vomiting and diarrhoea are a separate issue

Why could tirzepatide matter?

Tirzepatide slows stomach emptying, especially after the first dose, and can affect the absorption of some medicines taken by mouth. In a study described in EU Mounjaro information, a single tirzepatide dose changed blood levels of hormones from one combined oral contraceptive. Researchers measured hormone exposure, not pregnancy rates. The finding is specific to the studied preparations and cannot quantify an individual’s risk.3

What do US, UK and EU sources say?

The US Zepbound prescribing information advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting Zepbound and for four weeks after each dose increase. UK MHRA public guidance advises people using Mounjaro and an oral pill to add a barrier method for the same periods. EU Mounjaro information reports the measured hormone changes but says no oral-contraceptive dose adjustment is required. These are distinct regulatory assessments, not direct pregnancy-outcome comparisons. Check the current advice for your product and location with a healthcare professional.

If considering a switch, ask when the new method becomes effective and what protection is needed in the meantime; not all methods work immediately.123

What about semaglutide?

Do not assume every medicine in this group has the same interaction. UK NHS Specialist Pharmacy Service guidance says there is no evidence that semaglutide reduces oral contraception effectiveness in the same way; this is not proof that every individual situation is risk-free. Ozempic, Wegovy and Rybelsus are different semaglutide products, with product-specific instructions. Ask about your exact medicine and contraceptive, especially if you have vomiting or diarrhoea.4

Vomiting and diarrhoea are a separate issue

Vomiting or severe diarrhoea can affect absorption of an oral contraceptive, regardless of whether the weight or diabetes medicine has a direct interaction with it. The appropriate missed-pill instructions depend on the contraceptive and circumstances. Check its leaflet and seek prompt pharmacy or clinical advice; if pregnancy protection may have been interrupted, ask promptly whether emergency contraception or other action is relevant. Do not assume a non-oral contraceptive has the same absorption issue as a pill.42

Planning pregnancy or breastfeeding

Contraception, a possible pregnancy and planning pregnancy are related but different questions. Guidance and recommended intervals vary by medicine and jurisdiction. Speak with the prescriber promptly if pregnancy is possible or planned, and discuss treatment decisions rather than making changes based on a general article. See GLP-1 medicines and pregnancy and the tirzepatide and semaglutide profiles.

The UK MHRA advises against using GLP-1 medicines while breastfeeding because there is not enough safety information about possible effects on the baby. If you are breastfeeding or plan to breastfeed, speak with the prescriber about the exact medicine, feeding and treatment options. This is UK guidance; follow the advice of your own care team and local product information.2

Further reading

Trusted external resources selected to help explain this page. They open in a new tab.

  • US Zepbound prescribing information ↗US FDA / DailyMed · Check the oral-contraception warning. · Checked 4 Nov 2026US manufacturer label; recommendations are product- and jurisdiction-specific.
  • UK MHRA guidance on GLP-1 medicines ↗UK Medicines and Healthcare products Regulatory Agency · Check UK contraception and pregnancy guidance. · Checked 4 Nov 2026UK public guidance; current wording should be checked close to use.
  • EU Mounjaro product information ↗European Medicines Agency · Read the interaction study and EU assessment. · Checked 4 Nov 2026EU medicine information; measured hormone levels are not pregnancy rates.
  • NHS Specialist Pharmacy Service: GLP-1 interactions ↗NHS Specialist Pharmacy Service · Review professional guidance on contraception and digestive symptoms. · Checked 4 Nov 2026UK professional guidance; the exact contraceptive and product matter.

Sources, kept close.

Selected supporting sources; this is not a complete literature review.

  1. Zepbound (tirzepatide) prescribing informationUS FDA / DailyMed · US manufacturer product label, revised August 2026Accessed 2026-11-04
  2. GLP-1 medicines for weight loss and diabetes: what you need to knowUK Medicines and Healthcare products Regulatory Agency · UK regulator public guidance, updated February 2026Accessed 2026-11-04
  3. Mounjaro: European product informationEuropean Medicines Agency · EU regulator product informationAccessed 2026-11-04
  4. Considerations and interactions with GLP-1 receptor agonistsNHS Specialist Pharmacy Service · UK professional medicines guidance, updated November 2025Accessed 2026-11-04